Medically reviewed by 
Overview
For the first time, a GLP-1 weight loss treatment is coming to Europe as a once-daily tablet rather than an injection. In May 2026, the European Medicines Agency's expert committee (CHMP) recommended approval of the Wegovy pill — oral semaglutide for chronic weight management in adults, making it the first oral GLP-1 receptor agonist authorised for weight loss in the EU.
If you have been considering weight loss injections but hesitated because of needles, this is the development you have been waiting for. This guide covers what the Wegovy pill is, how it compares to the injections available today, when it is likely to reach Ireland, what it may cost, and what you can do right now while you wait.
The short version: the pill is approved but not yet on Irish pharmacy shelves. Novo Nordisk plans a phased launch in selected markets in the second half of 2026. You can register your interest with us today to be first in the queue, and if you don't want to wait, doctor-prescribed Wegovy and Mounjaro injections are available now, delivered from Northern Ireland at significantly lower cost than Republic of Ireland pharmacy prices.
What is the Wegovy pill?
The Wegovy pill contains oral semaglutide, the same active ingredient as the Wegovy injection, in tablet strengths of 1.5mg, 4mg, 9mg and 25mg. Like the injection, it works as a GLP-1 receptor agonist: it mimics a natural gut hormone that regulates appetite, slows stomach emptying, and reduces the constant "food noise" that undermines so many weight loss attempts.
The difference is purely the route into your body. Semaglutide is a peptide that the stomach would normally digest before it could work. The tablet solves this with an absorption enhancer (SNAC) that protects the molecule long enough for it to be absorbed, which is also why the pill must be taken on an empty stomach with a small sip of water, at least 30 minutes before food, drink or other medicines.
How effective is it? The OASIS 4 results
In the OASIS 4 clinical trial, adults with obesity (or overweight with a weight-related condition) taking the 25mg oral dose lost an average of 16.6% of their body weight, with about a third of participants losing 20% or more. That puts the pill broadly in line with the Wegovy 2.4mg injection (around 15% average loss in the STEP 1 trial) a remarkable result for a tablet.
For comparison, Mounjaro (tirzepatide), the dual GLP-1 + GIP injection, remains the most effective option studied, with average losses around 20% at 72 weeks in SURMOUNT-1. You can read more in our guide to GLP-1 vs GLP-1 + GIP treatments.
When will the Wegovy pill be available in Ireland?
Here is the honest timeline, based on what has been confirmed:
- 21 May 2026 CHMP adopted a positive opinion recommending the new tablet form in the EU.
- H2 2026 Novo Nordisk has said it plans to launch the pill in selected markets outside the US in the second half of 2026. Which markets come first has not been confirmed.
- 2027–2028 Novo Nordisk is investing €432 million in its Athlone facility in Co. Westmeath to manufacture the oral pill for global markets, with capacity coming online from late 2027. Ireland will literally be making this medicine.
Realistically, Irish patients should expect availability between late 2026 and 2027, subject to launch sequencing and supply. Any product on the Irish market will be regulated by the HPRA, and it will be prescription-only, no legitimate supplier can sell it to you without a prescription, and anyone offering "Wegovy pills" online today should be treated as a red flag.
What will the Wegovy pill cost in Ireland?
Pricing has not been announced. As a guide, Wegovy injections currently cost roughly €240-€355 per month at Republic of Ireland pharmacy prices, while our patients access equivalent treatment delivered from Northern Ireland for materially less. Novo Nordisk has priced the pill comparably to the injection in the US market; if that pattern holds in Europe, expect monthly costs in a similar band to the injectable, and expect the same North–South price gap we already see with injections. We will publish a full price comparison the day pricing is confirmed.
Pill or injection: which will suit you?
The pill will suit people who cannot tolerate the idea of a weekly self-injection. But it is worth weighing honestly:
- Dosing: the pill is taken every day on an empty stomach with strict timing rules; the injection is once a week, any time.
- Effectiveness: oral semaglutide 25mg (~16.6%) sits close to injectable Wegovy (~15%) but below Mounjaro (~20%).
- Side effects: the profile is similar, mainly nausea, constipation, and diarrhea when starting or increasing the dose.
- Availability: Injections are available in Ireland now; the pill is not.
Our full comparison: Wegovy weight loss injections in Ireland — a complete guide.
Risks and side effects
Oral semaglutide carries the same core cautions as injectable GLP-1s. The most common side effects are gastrointestinal, nausea, vomiting, diarrhea, constipation, usually worst during dose escalation and easing with time. It is not suitable for people who are pregnant or breastfeeding, or who have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Rare but serious risks include pancreatitis and gallbladder disease. Always review the EMA product information and discuss your medical history with a doctor before any treatment.
What you can do today
- Register your interest in the Wegovy pill. We will contact you the moment Irish availability and pricing are confirmed, register via WhatsApp.
- Check your eligibility. Treatment is generally appropriate for adults with a BMI of 30+, or 27+ with a weight-related condition, check your BMI here.
- Don't put your health on hold. Wegovy and Mounjaro injections are available now through our doctor-led service, prescribed by an Irish-registered doctor and delivered from a licensed Northern Ireland pharmacy at prices typically €90–€280 per month below Republic of Ireland pharmacy costs. The online consultation is a flat €30, the same for first and repeat consultations, fully refunded if you are not eligible.
Frequently asked questions
Is the Wegovy pill available in Ireland now?
No. The European Medicines Agency's expert committee (CHMP) issued its positive opinion on 21 May 2026, and EU marketing authorisation followed, but approval and availability are two different things. Novo Nordisk has confirmed a phased launch starting in selected markets outside the US in the second half of 2026, and has not published the country sequence. Ireland's realistic window is late 2026 to 2027, and initial supply may be constrained, as it was when Wegovy injections first launched. Registering your interest with us costs nothing and means you'll be contacted the day we can prescribe it, with confirmed Irish pricing, rather than finding out weeks later.
Is the pill as effective as the injection?
For semaglutide, effectively yes. In the OASIS 4 trial, adults taking the 25mg daily tablet lost an average of 16.6% of their body weight, with roughly one in three losing 20% or more. The Wegovy 2.4mg weekly injection produced an average of about 15% in its own pivotal trial (STEP 1, 68 weeks). Those are different trials with different participants, so small gaps shouldn't be over-read; the fair summary is that the tablet matches the injection. Mounjaro remains the most effective option studied, with an average loss of roughly 20% over 72 weeks, because it targets two hormone receptors rather than one. Which suits you depends on your history, goals, and tolerability; that's the €30 consultation conversation.
Will I need a prescription?
Yes, always. Oral semaglutide is a prescription-only medicine across the EU and UK, exactly like the injections, and that will not change at launch. A doctor must first confirm you meet the licensed criteria, generally a BMI of 30+, or 27+ with a weight-related condition, and screen for contraindications like pregnancy, a history of medullary thyroid cancer or MEN2, and interactions with your existing medicines. This matters for safety in another way too: because launch demand will be intense, counterfeit "Wegovy pills" will appear online before the real product reaches Irish patients. Any website offering it without a prescription today is, by definition, not selling the genuine medicine.
Can I switch from injections to the pill later?
Yes, and this is worth understanding, because it removes the main reason people delay treatment. The pill and the Wegovy injection contain the same molecule, so transitioning is a dose-mapping exercise your prescribing doctor manages, not a restart. Patients on Mounjaro can also switch to oral semaglutide, though the doctor will discuss the effectiveness trade-off first. What you don't get back by waiting is time: a patient who starts injections this month will typically have lost 10–15% of their body weight by the time the pill reaches Irish pharmacies. Starting now and switching later, if the pill still appeals, is the strategy our doctors expect most patients to take.
What does it cost to find out if I qualify?
€30, flat, and that's the whole fee structure, not an introductory rate. The same €30 applies to your first consultation and every repeat review, including dose changes, so ongoing medical supervision never carries a surprise cost. If our doctor assesses you and concludes treatment isn't suitable or safe for you, the €30 is refunded in full, you only pay for a consultation that gives you a real treatment pathway. Compare that with typical online clinic fees of €50–€120 per consultation, or a private GP visit at €60–€80 before pharmacy prices even enter the picture.
References
- EMA: First oral GLP-1 treatment for weight management
- EMA: Wegovy — opinion on variation to marketing authorisation
- Novo Nordisk CHMP announcement, 22 May 2026
- STEP 1 trial, NEJM · SURMOUNT-1 trial, NEJM
- Health Products Regulatory Authority (HPRA)
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. All prescription treatment decisions are made by an Irish-registered doctor following individual medical assessment. Results vary between individuals. If you have questions about your health, consult a qualified healthcare professional.
